Last reviewed · How we verify

NCT04526054

Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients

Completed NA Last updated 3 August 2022
What this trial tests

NA trial testing ENT exam in Olfaction Disorders in 13 participants. Completed in 3 September 2021.

Timeline
3 September 2020
Primary endpoint
3 September 2021
3 September 2021

Quick facts

Lead sponsorHopital Foch
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment13
Start date3 September 2020
Primary completion3 September 2021
Estimated completion3 September 2021
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Hopital Foch — full company profile →

Who can join

18 and older, any sex, with Olfaction Disorders or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients. This study aimed to detect these disturbances among positive COVID-19 patients (symptom not initially highlighted by the patient and not sought by caregivers) in order to allow early management of olfactory and gustatory dysfunction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. SARS-Cov-2 Damage on the Nervous System and Mental Health.
    Boulkrane MS, Ilina V, Melchakov R, Arisov M, et al · · 2022 · cited 4× · PMID 34191699 · DOI 10.2174/1570159x19666210629151303

Verify or expand the search:

Other recruiting trials for Olfaction Disorders

Currently open trials in the same condition.

Other Hopital Foch trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04526054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing